Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387738 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
A Phase 2 study, sponsored by Dynavax Technologies Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 738
- Enrollment target
NCT00387738: Clinical Trial Phase 2 study, sponsored by Dynavax Technologies Corporation.
NCT00387738 is a Phase 2 study that was terminated before completion, run by Dynavax Technologies Corporation. The registered enrollment target is 738 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (455% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387738, a Phase 2 study, was terminated before completion, sponsored by Dynavax Technologies Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 738 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if a new investigational vaccine, TOLAMBA™, is safe and effective in reducing the symptoms of ragweed allergy.
Interventions
- BIOLOGICAL Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
- BIOLOGICAL Histamine base
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Why NCT00387738 stopped before completion
NCT00387738 is an interventional study that assigns participants to a tested intervention. The registered 738 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (455% higher).
The record links to 0 conditions, and to 2 interventions - of which Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate is the first listed.
NCT00387738 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00387738 about?
NCT00387738 is a clinical study titled "Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults". The purpose of this study is to find out if a new investigational vaccine, TOLAMBA™, is safe and effective in reducing the symptoms of ragweed allergy.
What is the current status of trial NCT00387738?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 738 participants. The study started on 2006-04. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00387738?
The interventions under investigation include: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate (BIOLOGICAL), Histamine base (BIOLOGICAL).
Who is sponsoring clinical trial NCT00387738?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00387738's enrollment target sits among peer trials
738 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03723928 · 739 participants · NA
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia